Grouping and Worksharing Under the 2025 EU Variations Guidelines: A Practical Approach

    The European Commission's revised Variations Guidelines, published in September 2025, introduced changes that go beyond how variations are classified. They also provide clearer options for managing related post-authorisation changes through grouping and coordinated worksharing procedures.

    For Marketing Authorisation Holders (MAHs), the opportunity is straightforward: fewer duplicated activities and better coordination across the product lifecycle. But the benefits depend on how changes are identified, justified and planned.

    The question is not simply whether variations can be combined. It is whether combining them makes scientific and operational sense.

    In This Blog Post

    • How to identify variations that are suitable for grouping
    • What the wider worksharing scope means for MAHs and partners
    • Why portfolio planning matters for Type IA updates and other changes
    • Three practical questions to ask before choosing a submission strategy

    Making Effective Use of Variation Grouping

    Grouping variations into one submission is not new. The 2025 Guidelines, however, systematise the available scenarios and provide a clearer framework for combining changes, including broader arrangements sometimes described as super-grouping.

    For example, a labelling update may be linked to a manufacturing change, or several quality changes may arise from the same underlying cause. Where the applicable conditions are met, coordinating such changes may be more efficient than treating each as a separate regulatory exercise.

    Grouping Needs a Clear Rationale

    The real challenge is not identifying every change that might technically be grouped. It is deciding which changes belong together. A shared scientific or procedural rationale, compatible documentation and realistic submission timing all matter.

    Forcing unrelated changes into one package solely to reduce fees or timelines can create the opposite result. Questions from authorities, additional documentation or delays affecting the whole group may outweigh the expected savings.

    A practical starting point is a rolling three- to six-month view of planned variations. This allows regulatory teams to identify genuine connections early, rather than deciding on grouping only when individual submissions are almost ready.

    Worksharing Across a Wider Scope

    Worksharing offers another opportunity to coordinate regulatory assessment. Under the revised framework, its scope can extend beyond variations submitted by a single MAH, subject to the relevant legal and procedural conditions. This is particularly relevant when products held by different organisations are connected through a common origin, such as an active substance or manufacturing arrangement.

    For companies operating under licensing agreements, co-marketing structures or shared manufacturing networks, worksharing may reduce duplicated assessment efforts across related products.

    Coordination Comes Before Submission

    The challenge is organisational as much as regulatory. Different MAHs may have their own documentation standards, decision-making processes and timelines. Before pursuing worksharing, partners need to agree on who will coordinate the procedure and how the required information will be assembled.

    Useful questions include: Who leads the preparation? Which changes and products are in scope? Can the supporting evidence be aligned? How will partners manage authority questions and implementation timelines?

    Existing supply, licensing or development agreements may provide a starting point, but they should not be assumed to cover the responsibilities of a coordinated regulatory procedure.

    Worksharing is most valuable when the participants are ready to work together, not merely when their products have something in common.

    Managing Variations Across the Product Portfolio

    Grouping and worksharing are easier to use when variations are visible across a portfolio rather than managed one by one. The revised framework's annual Type IA update cycle reinforces this need for structured planning and tracking.

    Instead of treating each minor change as an isolated notification, teams need a reliable record of implemented changes and a clear view of when and how they will be reported under the applicable requirements.

    A lifecycle planning process aligned with the principles of ICH Q12 can support that shift. But an elaborate system is not necessarily the first step. A shared tracker may already make a meaningful difference.

    What Should a Variation Tracker Capture?

    At a minimum, a practical overview could include:

    • The planned or implemented change and its scientific rationale
    • Affected products, authorisations and markets
    • Expected variation classification and relevant deadlines
    • Potential grouping or worksharing opportunities
    • Internal owners, external partners and dependencies
    • Submission status and any required follow-up

    This gives Regulatory Affairs, Quality, Manufacturing and other functions a common view of upcoming changes. It also makes it easier to spot connections before submission plans become fixed.

    Where to Start: Three Questions for Regulatory Teams

    The transition does not need to happen all at once. Start with variations expected over the coming months and ask:

    • Do any planned changes share a scientific or procedural rationale that could support grouping?
    • Do any changes affect products, sites or arrangements involving other MAHs where worksharing may be possible?
    • Do we have a reliable process to track Type IA changes ahead of the applicable annual update deadline?

    The answers will help identify where the new framework can genuinely reduce effort and where additional coordination may be needed. They also make it easier to decide when separate submissions remain the more practical option.

    From Individual Submissions to Better Lifecycle Planning

    The revised Variations Guidelines create opportunities, but they do not remove the need for sound regulatory judgement. Grouping should be supported by a clear rationale. Worksharing requires alignment between the relevant parties. Annual Type IA reporting depends on accurate, ongoing change tracking.

    The goal is not to combine as many variations as possible. It is to manage changes in a way that is proportionate, coordinated and sustainable.

    A portfolio-level view helps teams make those choices earlier and with fewer surprises. It turns grouping and worksharing from last-minute procedural options into deliberate parts of lifecycle management.

    Make the Most of the Revised EU Variations Framework

    QbD Group supports pharmaceutical companies with Regulatory Affairs and lifecycle management, including variation strategy, submission planning, regulatory intelligence and coordination across products and markets.

    Want to identify where grouping or worksharing could improve your variation processes? Get in touch with our Regulatory Affairs experts to build a practical, portfolio-led approach.

    Main Sources

    • European Commission, Communication C/2025/5045 (22 September 2025): Guidelines on the categories of variations
    • European Medicines Agency: Post-authorisation guidance and variations
    • Heads of Medicines Agencies / CMDh: Guidance on the revised variations framework
    • ICH Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management